Citigroup Inc Point Biopharma Global Inc. Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$6.67 - $9.71 $119,479 - $173,935	17,913 Added 21.88%	99,775 $665,000
Q2 2023 Aug 10, 2023	SELL	$6.86 - $10.86 $380,160 - $601,828	-55,417 Reduced 40.37%	81,862 $741,000
Q1 2023 May 11, 2023	BUY	$6.78 - $8.1 $40,700 - $48,624	6,003 Added 4.57%	137,279 $998,000
Q4 2022 Feb 09, 2023	SELL	$5.72 - $9.78 $49,203 - $84,127	-8,602 Reduced 6.15%	131,276 $957,000
Q3 2022 Nov 10, 2022	BUY	$7.24 - $10.31 $555,525 - $791,086	76,730 Added 121.51%	139,878 $1.08 Million
Q2 2022 Aug 10, 2022	BUY	$5.6 - $9.5 $282,671 - $479,531	50,477 Added 398.37%	63,148 $430,000
Q1 2022 May 12, 2022	BUY	$5.46 - $8.13 $65,558 - $97,616	12,007 Added 1808.28%	12,671 $101,000
Q4 2021 Feb 10, 2022	BUY	$4.83 - $9.75 $3,207 - $6,474	664 New	664 $4,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.